PF-06671008 Dose Escalation Study in Advanced Solid Tumors
Status:
Terminated
Trial end date:
2019-03-29
Target enrollment:
Participant gender:
Summary
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses
of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin
expression. The study will then expand to look at the selected dose in patients with
P-cadherin expressing TNBC, CRC or NSCLC.